AIDS remains one of the greatest threats to health and development worldwide. More than two million people become newly infected with HIV and one million die each year despite significant investments and advancements in prevention and treatment. Infection rates remain disproportionately high in developing countries and within vulnerable populations.

Our understanding about the complexity of the HIV virus and the body’s immune responses continues to expand. However, we need to move faster and more effectively together to improve biomedical HIV prevention. No single organization has the expertise and capacity to accomplish this on its own.

IAVI aims to facilitate cross-sector collaboration to expedite the development of broadly effective vaccines and other new prevention options that we need to end AIDS. Specifically, IAVI is:

- Engaging the communities most at-risk of HIV infection
- Providing an integrated product development platform to accelerate the translation of promising concepts into HIV vaccine candidates for clinical testing
- Investing in high potential discovery programs that could transform HIV vaccine development and beyond
- Generating supportive data and messages to drive policies and investments that will help end the AIDS epidemic

A vaccine is needed to make this vision a reality. IAVI works across sectors and borders to accelerate the development of broadly effective AIDS vaccines and other new, biomedical prevention options that are safe, accessible and effective for use throughout the world.

Imagine a world without AIDS
Where to Find IAVI & Partners

IAVI Global Headquarters and Design & Development Laboratory
New York, NY

IAVI Neutralizing Antibody Center at The Scripps Research Institute
La Jolla, CA

IAVI Human Immunology Laboratory at Imperial College London
London

IAVI India and the HIV Vaccine Translational Research Laboratory
New Delhi

IAVI Eastern Africa
Nairobi

IAVI Southern Africa
Johannesburg

IAVI Europe
Amsterdam